• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EASL Recommendations on Treatment of Hepatitis C 2016.

出版信息

J Hepatol. 2017 Jan;66(1):153-194. doi: 10.1016/j.jhep.2016.09.001. Epub 2016 Sep 22.

DOI:10.1016/j.jhep.2016.09.001
PMID:27667367
Abstract
摘要

相似文献

1
EASL Recommendations on Treatment of Hepatitis C 2016.2016年欧洲肝脏研究学会丙型肝炎治疗指南
J Hepatol. 2017 Jan;66(1):153-194. doi: 10.1016/j.jhep.2016.09.001. Epub 2016 Sep 22.
2
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.丙型肝炎病毒核心抗原：一种简化的治疗监测工具，包括用于治疗后复发的情况。
J Clin Virol. 2017 Jul;92:32-38. doi: 10.1016/j.jcv.2017.05.007. Epub 2017 May 11.
3
HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients.丙型肝炎病毒核心抗原作为丙型肝炎病毒RNA的替代检测方法，用于评估丙型肝炎病毒1型感染患者对全口服、无干扰素治疗的病毒学反应。
J Virol Methods. 2017 Jul;245:14-18. doi: 10.1016/j.jviromet.2017.03.002. Epub 2017 Mar 27.
4
The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment.核心抗原检测对接受聚乙二醇干扰素/利巴韦林治疗的丙型肝炎患者管理的预测价值。
J Med Virol. 2004 Jul;73(3):392-6. doi: 10.1002/jmv.20104.
5
[Antigen and viral load].[抗原与病毒载量]
Transfus Clin Biol. 2003 Apr;10(2):74-7. doi: 10.1016/s1246-7820(03)00028-4.
6
Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response.治疗诱导的 HCV 核心抗原从血浆中清除可预测治疗结束时的病毒应答。
J Viral Hepat. 2013 Jan;20(1):65-71. doi: 10.1111/j.1365-2893.2012.01630.x. Epub 2012 Jul 4.
7
Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.同时感染人类免疫缺陷病毒和丙型肝炎病毒并接受干扰素加利巴韦林治疗的患者血清丙型肝炎病毒（HCV）RNA与核心抗原水平的比较
J Clin Microbiol. 2006 Feb;44(2):417-22. doi: 10.1128/JCM.44.2.417-422.2006.
8
Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment.丙型肝炎病毒核心抗原检测：在诊断、疾病监测及治疗中的作用
World J Gastroenterol. 2014 Jun 14;20(22):6701-6. doi: 10.3748/wjg.v20.i22.6701.
9
Hepatitis C virus core antigen testing in the monitoring of patients on dialysis.丙型肝炎病毒核心抗原检测在透析患者监测中的应用
Saudi J Kidney Dis Transpl. 2012 Sep;23(5):1056-8. doi: 10.4103/1319-2442.100951.
10
Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.在干扰素联合利巴韦林治疗慢性丙型肝炎患者期间，对总丙型肝炎病毒核心抗原检测、分支DNA检测和Amplicor监测检测在确定病毒血症方面的比较评估。
J Clin Microbiol. 2003 Jul;41(7):3212-20. doi: 10.1128/JCM.41.7.3212-3220.2003.

引用本文的文献

1
Ultrasonography Elastography to Predict the Diagnosis, Severity, and Treatment Indication of Esophageal Varices in Patients with Chronic Liver Diseases.超声弹性成像预测慢性肝病患者食管静脉曲张的诊断、严重程度及治疗指征
Diagnostics (Basel). 2025 Jul 25;15(15):1867. doi: 10.3390/diagnostics15151867.
2
Efficiency and safety of sofosbuvir in Bangladeshi children with chronic hepatitis C virus infection.索磷布韦治疗孟加拉国慢性丙型肝炎病毒感染儿童的有效性和安全性。
ILIVER. 2023 Jul 28;2(3):146-150. doi: 10.1016/j.iliver.2023.06.002. eCollection 2023 Sep.
3
Autoimmune manifestations and direct-acting antiviral drugs in Egyptian patients with hepatitis C virus infection: A cohort study.
埃及丙型肝炎病毒感染患者的自身免疫表现与直接抗病毒药物：一项队列研究。
J Int Med Res. 2025 May;53(5):3000605251339135. doi: 10.1177/03000605251339135. Epub 2025 May 20.
4
Long-Term Risk of Hepatic and Extrahepatic-Related Events After Direct Antiviral Therapy for Chronic Hepatitis C: A Prospective Long-Term Study Cohort.慢性丙型肝炎直接抗病毒治疗后肝脏及肝外相关事件的长期风险：一项前瞻性长期研究队列
Cancers (Basel). 2025 Apr 30;17(9):1528. doi: 10.3390/cancers17091528.
5
Prevalence and Risk Factors of Significant Hepatic Fibrosis in Omani Patients with HBeAg-negative Chronic Hepatitis B Virus Infection: A Retrospective Study.阿曼HBeAg阴性慢性乙型肝炎病毒感染患者显著肝纤维化的患病率及危险因素：一项回顾性研究
Oman Med J. 2024 Nov 30;39(6):e693. doi: 10.5001/omj.2024.113. eCollection 2024 Nov.
6
Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA.基于异常凝血酶原（PIVKA-II）的模型在接受直接抗病毒药物（DAA）成功治疗的丙型肝炎病毒（HCV）相关肝硬化患者肝癌风险分层中的开发与验证
Aliment Pharmacol Ther. 2025 Feb;61(3):538-549. doi: 10.1111/apt.18409. Epub 2024 Nov 21.
7
Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.慢性丙型肝炎感染患者以及初次或再次使用泛基因型直接抗病毒药物治疗后病毒学失败患者中耐药相关替代位点的流行率：一项系统评价和荟萃分析
Clin Infect Dis. 2024 Dec 17;79(6):1437-1446. doi: 10.1093/cid/ciae431.
8
Patient profiled data for treatment decision-making: valuable as an add-on to hepatitis C clinical guidelines?患者特征数据在治疗决策中的作用：作为丙型肝炎临床指南的补充是否有价值？
BMC Med Inform Decis Mak. 2024 Aug 13;24(1):227. doi: 10.1186/s12911-024-02608-x.
9
Understanding the relationship between HCV infection and progression of kidney disease.了解丙型肝炎病毒感染与肾脏疾病进展之间的关系。
Front Microbiol. 2024 Jun 28;15:1418301. doi: 10.3389/fmicb.2024.1418301. eCollection 2024.
10
Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study.不同病因肝细胞癌患者代谢综合征的患病率：一项回顾性研究
Infect Agent Cancer. 2024 May 1;19(1):21. doi: 10.1186/s13027-024-00575-6.